论文部分内容阅读
目的观察依那普利联合缬沙坦防治慢性心力衰竭(CHF)合并心房颤动(AF)的临床疗效。方法选择慢性心力衰竭合并阵发性房颤患者55例,随机分为观察组28例和对照组27例,对照组给予常规治疗,观察组在常规治疗基础上加用依那普利10 mg次/,2次/d,缬沙坦80 mg/次,1次/d,口服,疗程8周,治疗前及疗程结束后评价临床疗效及心功能变化。结果观察组治疗后新房颤动复发率为10.71%,对照组为22.22%,两组比较差异有统计学意义(P<0.01);治疗组心功能(NYHA)分级及左室射血分数(LVEF)较对照组改善明显,差异有统计学意义(P<0.05)。结论依那普利联合缬沙坦能明显改善慢性心力衰竭合并阵发性心房颤动患者的心功能分级及左室射血分数,并可降低心房颤动的复发率。
Objective To observe the clinical efficacy of enalapril combined with valsartan in the prevention and treatment of chronic heart failure (CHF) and atrial fibrillation (AF). Methods Fifty-five patients with chronic heart failure and paroxysmal atrial fibrillation were randomly divided into observation group (n = 28) and control group (n = 27). The control group was given routine treatment. The observation group was given enalapril 10 mg times /, 2 times / d, valsartan 80 mg / time, 1 time / d, oral, treatment for 8 weeks, before and after treatment evaluation of clinical efficacy and cardiac function changes. Results The recurrence rate of new fibrillation was 10.71% in the observation group and 22.22% in the control group, with significant difference between the two groups (P <0.01). NYHA class and LVEF, Compared with the control group, the improvement was significant (P <0.05). Conclusion Enalapril combined with valsartan can significantly improve cardiac function classification and left ventricular ejection fraction in patients with chronic heart failure complicated by paroxysmal atrial fibrillation and reduce the recurrence rate of atrial fibrillation.